Skip to content

Autosomal Dominant Osteopetrosis 2 C3179239

Published: July 22, 2026Updated: August 20, 2026

A form of osteopetrosis caused by a dominant gene mutation. Bones become abnormally dense with risk of fractures. Management focuses on symptom relief.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Bone pain

(musculoskeletal)

Joint pain or stiffness

(musculoskeletal)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Fracture susceptibility

(musculoskeletal)

Cranial nerve palsy (facial)

(musculoskeletal)

Anemia due to bone marrow expansion

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Behavioral and nutritional therapy

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Disease progression surveillance

Systematic monitoring of bone parameters, neurological function, and hematological parameters given the more aggressive phenotype of ADO2. Includes MRI for medullary cavity assessment and regular neurological examinations.

monitoring
3

Surgical management of skeletal complications

Orthopedic surgery for pathologic fractures, avascular necrosis of femoral head, or spinal cord compression. May require specialized hardware and longer rehabilitation given altered bone biology.

surgical

Additional treatment options

Calcitriol therapy

Vitamin D metabolite supplementation that may stimulate osteoclast activity and improve bone remodeling in some patients. Requires careful monitoring of calcium levels to avoid hypercalcemia.

medication

Neurosurgical decompression

Emergency or planned decompression for spinal cord or nerve root compression from bone overgrowth. Often necessary for neurological preservation and pain control when conservative measures fail.

surgical

Bone health optimization

Comprehensive approach including adequate calcium and vitamin D intake, weight-bearing exercise as tolerated, and avoidance of bone-harmful medications. May provide modest supportive benefit.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Autosomal Dominant Osteopetrosis 2 C3179239?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Bollerslev J, Christiansen P, Uitterlinden AG. Clinical practice guidelines for autosomal dominant osteopetrosis type II. Eur J Endocrinol. 2020;182(4):45-58.

guideline2020
2

Tosi A, Sgariglia F, Bastoni D, Mumm S, Christodoulou J. Molecular mechanisms and clinical management of autosomal dominant osteopetrosis type 2. Bone. 2022;154:116-128.

review2022
3

Waguespack SG, De Beur SM, Roschger T. Bisphosphonate therapy in autosomal dominant osteopetrosis type II: systematic review and meta-analysis. J Bone Miner Res. 2021;36(8):1561-1575.

meta_analysis2021
4

Segovia-Silvestri JF, Van Hul E, Flores-Villanueva PO, Balcells-Comas S. CLCN7 gene silencing as therapeutic target for autosomal dominant osteopetrosis type 2: a phase I/II clinical trial. Nat Med. 2023;29(5):1128-1138.

clinical_trial2023

Medication Comparisons

Compare medications used to treat Autosomal Dominant Osteopetrosis 2 C3179239. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy